RITUXIMAB IN COMBINATION WITH HIGH DOSE METHYLPREDNISOLONE FOR THE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA

We observed that high-dose methylprednisolone (HDMP) and rituximab (R) was well tolerated and had promising activity when used in combination to treat patients with fludarabine-refractory chronic lymphocytic leukemia (CLL). This prompted us to evaluate the use of these agents in frontline therapy. T...

Descripción completa

Detalles Bibliográficos
Autores principales: Castro, Januario E., James, Danelle F., Sandoval-Sus, Jose D., Jain, Sonia, Bole, Janet, Rassenti, Laura, Kipps, Thomas J.
Formato: Texto
Lenguaje:English
Publicado: 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761991/
https://www.ncbi.nlm.nih.gov/pubmed/19693094
http://dx.doi.org/10.1038/leu.2009.133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761991/
https://www.ncbi.nlm.nih.gov/pubmed/19693094
http://dx.doi.org/10.1038/leu.2009.133

Ejemplares similares